The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice

Apr 18, 2008Life sciences

A new mouse model of fatty liver disease with obesity and insulin resistance

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

C57BL/6 mice developed pronounced obesity, dyslipidemia, and insulin resistance after 23 weeks of a modified high-fat diet.

The novel NASH mouse model exhibited marked liver lesions, including severe fat accumulation, inflammation, and fibrosis.
Increased serum alanine aminotransferase (ALT) levels were observed in the model animals compared to controls.
Treatment with fenofibrate or rosiglitazone improved insulin sensitivity and corrected dyslipidemia in the NASH model.
Fenofibrate was found to be more effective than rosiglitazone in enhancing liver morphology and reducing ALT levels.
Long-term feeding with the modified high-fat diet significantly altered the expression of key genes related to liver metabolism.

AI simplified

Non-alcoholic steatohepatitis (NASH) is a hepatic manifestation of the metabolic syndrome that can progress to liver cirrhosis. The major aim of this study was to establish a novel NASH mouse model accompanied by obesity and insulin resistance, then explore the molecular mechanisms of NASH and evaluate the effects of both the peroxisome proliferator-activated receptor alpha (PPARalpha) agonist fenofibrate and the PPARgamma agonist rosiglitazone in this established NASH model. The novel model was induced in C57BL/6 mice by 23 weeks of ad libitum feeding of a modified high-fat diet (mHFD), with lower methinione and choline and higher fat content. In comparison to the controls, the model animals developed pronounced obesity, dyslipidemia and insulin resistance. Marked liver lesions characterized by severe steatosis, inflammation, fibrosis, increased hepatic triglyceride content, and elevated serum alanine aminotransferase (ALT) levels were observed in the models. In this novel model, treatment with fenofibrate or rosiglitazone significantly improved insulin sensitivity and corrected dyslipidemia; however, fenofibrate was more effective than rosiglitazone in improving hepatic morphology and ALT levels. Further study showed that long-term feeding of mHFD significantly increased expression of mRNA for hepatic PPARgamma, adipose fatty acid binding protein (ap2) and CD36 and suppressed expression of mRNA for hepatic PPARalpha and carnitine palmitoyl transferase-1a (CPT-1a). These results showed the successful establishment of the combined NASH and obese-insulin resistance mouse model. Additionally, aberrant expressions of hepatic PPARalpha and PPARgamma may play a major role in the pathogenesis of NASH by affecting hepatic lipogenesis and fatty acid oxidation in this novel model.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief